TORONTO--(BUSINESS WIRE)--
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF)
(“Satellos” or the “Company”), a
clinical-stage biotechnology company developing life-improving medicines to
treat degenerative muscle diseases, will present and participate at the
following investor conferences in April:
Oppenheimer Innovation on the Island
Format: Presentation
Date: Wed.,
April 9, 2025, 8:52 a.m. AST
Location: San Juan,
Puerto Rico
Piper Sandler Spring Biopharma Symposium
Format: Participation in 1x1 meetings
Date:
Wed., April 16, 2025
Location: Boston, MA
About Satellos Bioscience Inc.
Satellos is a clinical-stage drug development company focused on restoring
natural muscle repair and regeneration in degenerative muscle diseases.
Through its research, Satellos has developed SAT-3247, a first-of-its-kind,
orally administered small molecule drug designed to address deficits in muscle
repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos
has identified as capable of replacing the signal normally provided by
dystrophin in muscle stem cells to effect repair and regeneration. By
restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem
cells to divide properly and more efficiently, promoting natural muscle repair
and regeneration. SAT-3247 is currently in clinical development as a potential
disease-modifying treatment initially for DMD. Satellos also is leveraging its
proprietary discovery platform MyoReGenX™ to identify additional muscle
diseases or injury conditions where restoring muscle repair and regeneration
may have therapeutic benefit and represent future clinical development
opportunities. For more information, visit
www.satellos.com.
Investors: Liz Williams, CFO,
ir@satellos.com
Media: Emily Williams, Senior Director,
Communications,
eawilliams@satellos.com
Clinical Trial Info: medicalinfo@satellos.com
Source: Satellos Bioscience Inc.